Andere Sprachen NervGen Pharma Corp.

Aktien

A2QP3D

CA64082X2032

NGEN

Markt geschlossen - Toronto S.E. Andere Börsenplätze 21:59:59 03.05.2024			% 5 Tage	% 1. Jan.
2,33 ^CAD	+7,87 %		+10,43 %	-13,70 %

17.04.	NervGen meldet für das Geschäftsjahr 2023 einen Nettoverlust von $0,38 pro Aktie und gibt ein operatives Update	MT
17.04.	NervGen Pharma Corp. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

NervGen Engages Russo Partners LLC to Provide Public Relations Services	25.04.
NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update	17.04.
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates	17.04.
NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	17.04.
Non-Opioid Revolution: Beacons of Hope in Opioid Crisis and a $50 Million Spin-Off	09.04.
NervGen Pharma Closes C$23 Million Bought Deal Financing	28.03.
NervGen Completes $23 Million Bought Deal Financing	28.03.
Canadian Investment Regulatory Organization Trade Resumption - NGEN	21.03.
NervGen Pharma Raising C$20.1 Million in Bought-Deal Offering of Share Units	21.03.
NERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERING	21.03.
Canadian Investment Regulatory Organization Trading Halt - NGEN	21.03.
NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company	21.02.
NervGen Pharma Grants Stock Options	20.02.
NervGen Pharma Corp. Plans to Initiate A New Study in Which Subjects Completes Open-Label Nvg-291	15.02.
NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury	15.02.
NervGen Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09.11.
NervGen Pharma Reports Q3 2023 Financial Results and Operational Updates	09.11.
Neuroscientist and NervGen Pharma Scientific Founder, Dr. Jerry Silver, Interviewed on 'Remarkable People' Podcast Hosted by Tech Luminary Guy Kawasaki	08.11.
NervGen Pharma Corp. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury	23.10.23
NervGen Pharma Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury	23.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen NervGen Pharma Corp.

Aktien

A2QP3D

CA64082X2032

NGEN

Andere Sprachen

Filter